Feasibility Trial on Combination of Platinum Doublets and Hypofractionated Radiotherapy for Locally-advanced Stage and / or Inoperable Non-small Cell Lung Carcinoma

Trial Profile

Feasibility Trial on Combination of Platinum Doublets and Hypofractionated Radiotherapy for Locally-advanced Stage and / or Inoperable Non-small Cell Lung Carcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Cisplatin (Primary) ; Etoposide (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms HYPOLAN
  • Most Recent Events

    • 28 Nov 2017 Planned End Date changed from 1 Jan 2022 to 2 Nov 2017.
    • 28 Nov 2017 Planned primary completion date changed from 1 Jan 2020 to 2 Nov 2017.
    • 28 Nov 2017 Planned initiation date changed from 1 Jan 2018 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top